We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0KCC market cap is 421.31M. The company's latest EPS is USD -3.4769 and P/E is -0.96.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 5.23M | 7.73M | 31.98M | 7.27M |
| Operating Income | -22.52M | -31.26M | -74.48M | -18M | -23.85M |
| Net Income | -22.43M | -29.93M | -64.1M | -73.42M | -28.72M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 39.86M | 55.42M | 159.56M | 100.09M | 74.89M |
| Total Liabilities | 9.02M | 21.94M | 94.35M | 60.5M | 49.3M |
| Total Equity | 30.84M | 33.48M | 65.22M | 34.29M | 20.47M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -19.72M | -25.98M | -35.94M | -45.57M | -23.33M |
| Investing | -12.42M | -11.75M | -13.96M | -4.34M | -932k |
| Financing | 47.87M | 22.8M | 78.75M | 35.81M | 12.19M |
| Market Cap | 421.31M |
| Price to Earnings Ratio | -0.96 |
| Price to Sales Ratio | 3.8 |
| Price to Cash Ratio | 2.93 |
| Price to Book Ratio | 1.08 |
| Dividend Yield | - |
| Shares Outstanding | 8.26M |
| Average Volume (1 week) | 40 |
| Average Volume (1 Month) | 119 |
| 52 Week Change | 0.00% |
| 52 Week High | 51.00 |
| 52 Week Low | 51.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Oncocyte Corp |
| Address |
15 cushing irvine, california 92618 |
| Website | https://www.oncocyte.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
